SynthesisBMC cancer2025
Exploring the potential clinical value of shear wave elastography in prostate cancer: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- A Dual-Transducer Approach for High-Resolution and High-Precision Shear Wave Elasticity Imaging.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential role of shear wave elastography (SWE) in prostate cancer (PCa) remains unclear. We systematically searched PubMed, Web of Science, and the Cochrane Library databases to identify correlated studies up to Dec 2024. A total of 137 studies were identified for potential inclusion, and 11 studies were included, comprising 1551 PCa patients. The pooled sensitivity, specificity, and the area under the summary receiver operating characteristic curve (AUC) for detecting malignant prostatic nodules were 90% (95% CI, 81-95%), 75% (95% CI, 62-84%) and 90% (95% CI: 87, 92%) in per-patient analysis, respectively. The sensitivity, specificity, and AUC were 86% (95% CI: 72%, 95%), 86% (95% CI: 78%, 92%) and 92% (95% CI: 90%, 94%) in per-sextant analysis. Publication bias test addressed low significant small-study bias. We found that SWE may serve as a potential diagnostic strategy for PCa and may help to reduce the number of core biopsies. Since limited quantity and small sample size of included studies, further well-designed studies are strongly encouraged to address this promising strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.